Key Highlights

  • Inovio Pharmaceuticals (NASDAQ:INO) was up 195.48 percent to USD 1.78 after an FDA accelerated approval.
  • Atrium Therapeutics (NASDAQ:RNA) was up 15.84 percent to USD 9.58 after dosing its first patient in a cardiomyopathy trial.
  • CalciMedica (NASDAQ:CALC) was up 15.07 percent to USD 1.68 with no fresh news identified.
  • Precigen (NASDAQ:PGEN) was down 22.48 percent to USD 5.38 after a rival approval.
  • BeyondSpring (NASDAQ:BYSI) was up 14.00 percent to USD 0.7339 with no new announcement identified.

Inovio Pharmaceuticals (NASDAQ:INO): An Accelerated Approval Lifts a Penny Stock

Inovio Pharmaceuticals (NASDAQ:INO) was up 195.48 percent to USD 1.78 in pre-market trading on November 2, 2026. The shares remain a penny stock. A company announcement dated October 30, 2026 said the US Food and Drug Administration granted accelerated approval to VOCERYQ for adults with recurrent respiratory papillomatosis.

In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months. The company expects a full commercial launch in the first quarter of 2027, and the FDA requires a draft confirmatory study protocol by the end of 2026. Cash was USD 36.7 million at June 30, 2026, excluding USD 18.3 million of net July offering proceeds. A short runway raises the prospect of further dilution.

Atrium Therapeutics (NASDAQ:RNA): A First Patient Dosed in a Rare Heart Trial

Atrium Therapeutics (NASDAQ:RNA) was up 15.84 percent to USD 9.58 in pre-market trading on November 2, 2026. No announcement dated that day was identified. The nearest news is a release dated October 27, 2026 saying the first patient had been dosed in a Phase 1/2 study of ATR 1072 for PRKAG2 syndrome, which plans to enroll about 37 participants.

Initial proof-of-concept data is expected in the second half of 2027, so no efficacy data is due in the near term. A private Placement priced on October 8, 2026 raised about USD 50 million at USD 7.93 per share, and the pre-market price is about 20.8 percent higher (calculated). An investor letter made public on October 20, 2026 called for a strategic review. Early-stage clinical risk and price swings remain central.

CalciMedica (NASDAQ:CALC): A Low-Priced Biotech Moving Without News

CalciMedica (NASDAQ:CALC) was up 15.07 percent to USD 1.68 in pre-market trading on November 2, 2026. No press release or filing dated between late October and November 2, 2026 was identified. Without a catalyst, the move looks more like momentum in a thinly traded, low-priced biotech share, which is a measured reading and not a confirmed cause.

The clinical-stage company develops Auxora and plans a Phase 1b study in pulmonary arterial hypertension, with data expected in mid-2027. Cash and equivalents were USD 18.6 million as of June 30, 2026, with runway guided into the second half of 2027. A one-for-five reverse split took effect on August 31, 2026, and warrants from a June private placement create dilution risk.

Precigen (NASDAQ:PGEN): A Single-Product Company Meets a Competitor

Precigen (NASDAQ:PGEN) was down 22.48 percent to USD 5.38 in pre-market trading on November 2, 2026. The decline follows news that Inovio's Voceryq won FDA accelerated approval for adults with recurrent respiratory papillomatosis, the only indication Precigen currently sells into.

PAPZIMEOS net product sales were USD 74.7 million in the first half of 2026, against total Revenue of USD 78.2 million. Dependence on one product means competitive entry, pricing pressure or slower uptake could matter more than for a diversified business. Third quarter results are due on November 4, 2026, with a call at 4:30 PM ET.

BeyondSpring (NASDAQ:BYSI): A Sub-Dollar Oncology Name With No Fresh Headline

BeyondSpring (NASDAQ:BYSI) was up 14.00 percent to USD 0.7339 in pre-market trading on November 2, 2026. No company press release or filing was identified for the period from late October through November 2, 2026. Shares priced below USD 1 often move sharply on thin volume, so this Penny Stock may be reacting to sentiment alone.

The company is focused on DUBLIN-4, a confirmatory Phase 3 study of plinabulin plus docetaxel in non-squamous, EGFR wild-type non-small cell lung cancer, planning to enroll 442 patients. Cash and short-term investments from continuing operations were USD 6.5 million as of June 30, 2026, against a first half net loss of USD 12.4 million. That gives roughly 3 months of coverage at that pace (calculated), which suggests further funding will be needed.

Where Things Stand

The Inovio approval is the thread connecting this group. It lifted Inovio and pressured Precigen, the incumbent in the same indication, while Atrium, CalciMedica and BeyondSpring moved without an announcement dated November 2, 2026. Three of the five trade near or below USD 5 and can be volatile and thinly traded. Items to watch include the Precigen report on November 4, 2026, Inovio shipping and its confirmatory protocol, the Atrium trial enrollment and the BeyondSpring cash position.